Kornimate/medical-research-clean huggingface dataset:
multimodal machine learning for auxiliary diagnosis of eye diseases

Conditions: Eye Diseases

Summary: with rapid advancements in natural language processing and image processing, there is a growing potential for intelligent diagnosis utilizing chatgpt trained through high-quality ophthalmic consultation. furthermore, by incorporating patient selfies, eye examination photos, and other image analysis techniques, the diagnostic capabilities can be further enhanced. the multi-center study aims to develop an auxiliary diagnostic program for eye diseases using multimodal machine learning techniques and evaluate its diagnostic efficacy in real-world outpatient clinics.


Eligibility criteria:
inclusion criteria: * informed consent obtained; * participants should be able to have chinese as their mother tongue, and be sufficiently able to read, write and understand chinese; * for normal participants: individuals should have no concerns related to their eyes. * for participants with eye-related chief complaints: individuals should have specific concerns or issues related to their eyes. exclusion criteria: * incomplete clinical data to support final diagnosis; * patients who, in the opinion of the attending physician or clinical study staff, are too medically unstable to participate in the study safely.
an open study to investigate the safety and efficacy of replenine®-vf in severe haemophilia b patients

Conditions: Haemophilia B

Summary: to compare the first and second recovery assessments on replenine®-vf and to evaluate recovery of different batches if patients changed batches during the study. to evaluate replenine®-vf in terms of long-term clinical efficacy, tolerance and safety


Eligibility criteria:
inclusion criteria: * previously treated patients * at least 12 years of age * severe haemophilia b and without inhibitor to factor ix exclusion criteria: -
a prospective study of microalbuminuria in untreated boys with alport syndrome

Conditions: Alport Syndrome; Kidney Disease

Summary: the goal of the microalbuminuria in untreated boys with alport syndrome study is to gather information about critical clinical time points such as when patients with small amounts of protein (microalbuminuria) in their urine progress to larger amounts (overt proteinuria). large amounts of protein in the urine is often an early sign of kidney disease. information needs to be collected in boys who are not taking medications known as angiotensin converting enzyme inhibitor (acei) or angiotensin receptor blocker (arb) in order to obtain accurate data about the length of time between the onset of microalbuminuria and the start of overt proteinuria. this new information will give physicians a better understanding of how to treat patients with alport syndrome. the information we gather by conducting this study will aid in planning future clinical trials because the identification of time points in disease progression, such as microalbuminuria and overt proteinuria, could reduce the time necessary to show a clinical benefit of a new treatment option. the study has been approved by the university of minnesota's institutional review board.

study aims 1. to determine the average ages of onset of microalbuminuria and overt proteinuria in untreated boys with alport syndrome 2. to determine the average duration of microalbuminuria before transition to overt proteinuria in untreated boys with alport syndrome this study does not involve treatment and is anticipated to last 3-5 years.

Eligibility criteria:
inclusion criteria: * diagnosis of alport syndrome, confirmed by skin biopsy, kidney biopsy, or molecular genetic analysis * diagnosis of alport syndrome, based on presence of hematuria and confirmed diagnosis of alport syndrome in a first-degree relative * male gender * absence of overt proteinuria, defined as urine protein:creatinine ratio less than 0.2 mg/mg * subject is not currently receiving treatment with an angiotensin converting enzyme inhibitor (acei) or angiotensin receptor blocker (arb) exclusion criteria: * female gender * presence of overt proteinuria * current treatment with acei or arb * end-stage kidney disease (on dialysis or kidney transplant recipient)

Keywords: microalbuminuria proteinuria
effect of intermittent thetaburst stimulation in treatment-resistant bipolar depression

Conditions: Bipolar Depression

Summary: the aim is to evaluate the evaluate the clinical interest and the safety of repetitive transcranial magnetic stimulation (rtms) delivered as intermittent theta burst stimulation(itbs) on severity of depression in patients with treatment-resistant bipolar disorder.

methods: a double-blind randomized sham-controlled pilot study will be conducted in 40 patients with bipolar treatment-resistant depression receiving either active (n=20) or sham (n=20) itbs over the left dorsolateral prefrontal cortex. depression severity will be assessed by an investigator blinded to itbs condition before and after 10 to 30 itbs sessions depending on remission onset. remission will be defined as beck depression inventory, bdi score\<10. objective/hypothesis: the investigators hypothesized the superiority of active itbs over sham itbs

Eligibility criteria:
inclusion criteria: * bipolar disorder according to diagnostic and statistical manual of mental disorders, dsm-iv criteria * montgomery and asberg depression scale \> 20 exclusion criteria: * other psychiatric features, rapid cycles * benzodiazepines intake * pregnancy
an expanded access program of cretostimogene grenadenorepvec for treatment of nmibc for patients unresponsive to bcg

Conditions: Non-Muscle Invasive Bladder Cancer; Urothelial Carcinoma; Urologic Cancer; Bladder Cancer

Summary: this is an open-label, expanded access trial designed to provide access to cretostimogene in patients with nmibc (specifically cis with or without hg ta/t1) unresponsive to bcg.

all participants will be assigned the same treatment schedule. participants will receive an induction course of 6 weekly treatments, and, if there is no disease recurrence at week 13, participants will receive a cycle of 3 weekly treatments up to week 15. if there is persistent hg ta and/or cis at week 13, participants may receive a second induction cycle. if the participant has persistent but improved hg ta and/or cis at week 25 or a later timepoint, the participant may receive a cycle of 3 weekly treatments of cretostimogene at the discretion of the investigator provided that t1 or higher stage of urothelial carcinoma is not present. if there is no disease present at week 25 or a later timepoint, participants will receive a cycle of 3 weekly treatments every 12 weeks through month 12. after month 12, participants will receive a cycle of 3 weekly treatments every 6 months through the last treatment cycle at month 24, or until discontinuation from the study treatment. disease status will be assessed based on local standard of care (which may include urine cytology, cystoscopy, and directed turbt/biopsy) every 12 weeks. ctu/mru can be done per standard of care evaluation at investigator's discretion.

Eligibility criteria:
inclusion criteria: 1. have pathologically confirmed bcg unresponsive cis. there is no maximum limit to the amount of prior bcg treatment, but maintenance bcg should be administered on a schedule consistent with standard induction-maintenance protocols. specifically, the definition of bcg unresponsive cis will also require the following: * pathologically confirmed relapsed or persistent cis (with or without hg ta or hg t1 disease) * completion of qualifying bcg treatment (e.g., "5+2" minimum exposure) within 15 months of the initial qualifying dose of bcg. 2. have all ta and/or t1 disease and all cis resected or fulgurated, as feasible, prior to study treatment 3. ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy according to investigator assessment. 4. acceptable baseline organ function exclusion criteria: 1. muscle invasive bladder cancer, locally advanced or metastatic bladder cancer. 2. has had active autoimmune or inflammatory disease requiring systemic treatment within 4 weeks of day 1. replacement therapy is not considered an excluded form of systemic treatment and is allowed. 3. has received systemic anticancer therapy, including investigational agents, within 4 weeks of day 1 4. is pregnant, currently breastfeeding or intending to breastfeed, beginning at screening through 1 week after the last study treatment.

Keywords: urology bladder cancer non muscle invasive bladder cancer cretostimogene grenadenorepvec
a study to evaluate efficacy, and safety of ql2107 plus chemo and compare with keytruda in participants with iv nqnsclc

Conditions: NSCLC

Summary: the goal of this clinical trial is to compare the efficacy similarities between ql2107 and keytruda in metastatic non-squamous nsclc.


Eligibility criteria:
inclusion criteria: * subjects who voluntarily participate, sign the informed consent form (icf), and are able to comply with the study procedures; * subjects aged ≥ 18 and ≤ 75 years at enrollment, male or female; * histologically or cytologically confirmed metastatic (stage iv) non-squamous nsclc as per the american joint committee on cancer (ajcc) 8th edition; if multiple tumor histologies are present, the predominant cell type should be classified; * no egfr sensitive mutations or alk gene translocations. * expected survival ≥ 3 months; * eastern cooperative oncology group (ecog) performance status score: 0 or 1; exclusion criteria: * pulmonary radiation therapy \> 30 gy within 6 months prior to the first dose; * palliative radiation therapy completed within 7 days prior to the first dose; * any other form of anti-tumor therapy expected to be required during the study; * uncontrolled or symptomatic pericardial effusion, pleural effusion and ascites requiring repeated paracentesis and drainage; * presence of metastases to brain stem, meninges and spinal cord or compression;
impact of pediatric acute renal injury in severe sepsis in young adults

Conditions: Acute Kidney Injury; Chronic Kidney Disease; Hypertension

Summary: sepsis is the most common cause of childhood death worldwide. millions of children survive, but are left with impaired health. sepsis-related acute kidney injury (saki) is increasingly recognized as a significant factor associated with long-term mortality among different patient populations. renal dysfunction and subsequent chronic kidney disease is implicated in the development of hypertension and cardiovascular disease. the investigators overall hypothesis is that, in the pediatric population, sepsis-related aki will have unrecognized, long-term consequences with regard to kidney function, endothelial function, blood pressure control, and overall health.

this will be a two-arm cross-sectional control-cohort outpatient evaluation. subjects with saki and a random selection of non-saki subjects who agree to participate in another study of quality of life survey will be asked to participate in the outpatient study. subjects will be asked to come in to the clinical research center for 24-hour monitoring and participate in the outpatient study where urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by blood pressure monitoring, peripheral arterial and applanation tonometry.

Eligibility criteria:
inclusion criteria: for all patients: • age 18-24 at time of participation in the study for non-aki sepsis patients: * hospitalization with a diagnosis of sepsis from 1998-2014 * failure to meet pedrifle criteria for aki during incident sepsis admission * participation in cognitive survey study with completion of the pedsql survey for saki patients: * hospitalization with a diagnosis of sepsis from 1998-2014 * severe aki as defined by the pedrifle criteria during incident sepsis admission * participation in cognitive survey study with completion of the pedsql survey exclusion criteria: for all patients: * known pre-existing ckd as defined by history of kidney transplant or long-term dialysis * age greater than 18 years at the time of incident sepsis admission * aki from primary kidney disease including acute glomerulonephritis and obstructive uropathy * pregnancy at the time of enrollment * known or suspected allergy to gadolinium based contrast * known or suspected allergy to iodine or shellfish will be excluded from rpf measurement with iodohippurate * heart failure or condition whereby the administration of 0.9% normal saline would be contraindicated

Keywords: acute kidney injury
factors affecting the prognosis of patients with endometrial cancer

Conditions: Endometrial Cancer

Summary: endometrial cancer is the second common gynecologic malignancy in taiwan. the prevalence has been overcome the epithelial ovarian cancer because of the change of life style to western style recently. most patients with endometrial cancer are stage i \& ii, the most histology is still "endometrioid adenocarcinoma" (type i endometrial cancer). in statistics, advanced stage (figo stage iii and iv) is approximately 16% of all cases. most patients has good outcome of endometrial cancer because their surgical stage is belonged to "early stage". however, the recurrence, distant metastases and mortality are high if the diseases is confirmed to be advanced stage. the adjuvant therapies after staging/debulking operation are systemic chemotherapy and whole pelvic radiation therapy/ brachytherapy. whether the adjuvant therapy can cure the disease of not is still controversial. because of the rarity of the advanced endometrial cancer, varies adjuvant therapeutic modalities, eg. chemotherapy only, pelvic radiation therapy only, combination of chemotherapy and radiation therapy or sequential "sandwich" therapy were ever used for such group patients in each medical center. but the case number is insufficient and limited to show the survival or progression free benefit during the statistics. besides, the surgical procedures and adjuvant therapy for early endometrial cancer is still remained to be determined. the investigators are also interested to analyze the factors affecting their survival. the investigators will perform a retrospective study to review the data of patients with endometrial cancer in department of obstetrics \& gynecology in far eastern memorial hospital.


Eligibility criteria:
inclusion criteria: 1. time interval: from 1991 to date. 2. comprehensive surgical staging or debulking procedure. 3. all female patients with endometrial cancer who underwent surgery for endometrial cancer at far eastern memorial hospital. exclusion criteria: 1. not comprehensive staging/debulking procedure. 2. patients who died of postoperative complications within 30 days after surgery were excluded from the survival analysis.
safety study of regimens of sofosbuvir, gs-0938, and ribavirin in patients with chronic hepatitis c infection

Conditions: Hepatitis C, Chronic

Summary: this study was designed to assess the safety and efficacy of multiple interferon-free treatment regimens of sofosbuvir (sovaldi™; gs-7977; psi-7977) and gs-0938 (psi-352938) alone and in combination, with and without ribavirin (rbv). each regimen was to be evaluated over 12 and 24 weeks to identify the optimal duration of therapy to maximize the benefit (sustained virologic response \[svr\]) versus risk (safety and resistance).


Eligibility criteria:
inclusion criteria: * chronic hcv-infection * naive to all hcv antiviral treatment * otherwise healthy patients exclusion criteria: * positive test at screening for hbsag, anti-hbc igm ab, or anti-hiv ab * history of any other clinically significant chronic liver disease * medical history which the investigator considers the patient unsuitable for the study

Keywords: hepatitis c chronic hcv
reduction of pain caused by biologic drugs in psoriasis

Conditions: Psoriasis; Pain

Summary: injectable biologic drugs are used as a treatment of psoriasis. these injections can sometimes be associated with pain. in this study the investigators aim to reduce the pain by applying heat or ice to the skin 2-3 minutes before injecting the drug, and to compare the pain to injection without any heat or ice.

as part of their therapy, some patients with psoriasis require treatment with biologic drugs, which are injected into their skin. while these are very effective, patients may experience some pain or discomfort associated with the injection of these drugs. in this research study conducted at mount sinai hospital, the investigators aim to identify whether this injection-related pain can be reduced if the area of skin to be injected with the biologic drug is treated with either ice packs or heating for two to three minutes prior to the injection. the investigators' aim is to include a total of 110 patients into this study, who have been started by their physician on one of these biologic drugs, such as etanercept, adalimumab, ustekinumab, or receiving secukinumab as part of a research study. patients will be recruited at the dermatology department. patients who are receiving a biologic drug, which is injected subcutaneously (into their skin) are eligible to participate in this study. each patient will receive his/her injection at our study site, by a study doctor/investigator. the same designee should inject the subject all three times. each patient will receive a total of three of their biologic drug injections at the study site, so he/she can receive the injection once following pre-treatment with ice, once following pre-treatment with heating, and once without any pre-treatment. patients will then be asked to mark the intensity of the pain associated with the injection on a scale, consisting of a horizontal line, by placing a single mark on the scale. the order of pre-treatment with ice or heat, or no pre-treatment will be randomized among all subjects (1/3 will receive ice first, 1/3 will receive heat first, 1/3 will receive no treatment first; the same randomization ratio will apply for the second and third injections).

Eligibility criteria:
inclusion criteria: * patients requiring treatment with a biologic drug * subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give written, signed and dated informed consent before any study-related activity is performed exclusion criteria: * patients receiving concurrent therapeutic injections for other indications * patients who have taken analgesics within 12 hours of their injection * a past history of cold-, heat- or pressure-induced urticaria

Keywords: psoriasis biologics subcutaneous pain heat ice
an observational study called rover to learn more about how well vericiguat works in people who were newly treated with vericiguat in routine medical care in germany

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Summary: this is an observational study in which data already collected from people treated with vericiguat are studied. in observational studies, only observations are made without participants receiving any advice or any changes to healthcare. chronic heart failure with reduced ejection fraction (hfref) is a long-term condition that occurs when the heart is weak and cannot pump enough blood to the rest of the body with each heartbeat. this leads to a reduced supply of oxygen which the body requires to function properly. the common symptoms include breathlessness, weakness, fatigue, and swelling in the ankles and legs. if left untreated, heart failure can lead to other serious health problems, including damage to other organs, which may result in hospital stays and even death. vericiguat works by increasing the activity of an enzyme called soluble guanylate cyclase (sgc), which relaxes the blood vessels and allows more blood to flow through. as a result, the heart is able to pump better. vericiguat is available in germany for the treatment of hfref based on the results of a study called victoria. the victoria study showed that vericiguat helps in lowering the chances of death or hospitalization due to heart failure. however, there is limited information available about the use of vericiguat for the treatment of hfref under real-world conditions in routine medical care. the main purpose of this study is to collect information about how well vericiguat works in people with hfref who were newly treated with vericiguat. in addition, researchers will collect information about participants' basic characteristics, including their age, gender, other health conditions they might have, and the medicines they might be taking. the data will come from 2 german health databases including people who newly started vericiguat treatment between september 2021 and september 2023.


Eligibility criteria:
inclusion criteria: * patients with an initial prescription of vericiguat (index date) according to atc code c01dx22. * at least 18 years or older on the initial prescription of vericiguat. exclusion criteria: * no exclusion criteria for any population will be applied.

Keywords: hfref
use of the epidermal micrografts for wound healing after mohs or excisional surgery for skin cancer

Conditions: Neoplasm of Skin

Summary: this case series will assess the use of suction blister epidermal grafts harvested by a novel device on select patients that have wounds from mohs or excisional surgery.

this study evaluates a novel micrografting technique to determine how it will influence the healing and cosmetic result of selected post surgical wounds in 12 subjects. the epidermal expansion system (designed by momelan technologies) will generate an array of small microblisters and transfer the micrografts to a sterile wound dressing for application to the subject's surgical area. the sponsor hypothesizes that applying expanded micrografts to wounds that otherwise would have healed by second intention alone will hasten healing and possibly reduce scarring.

Eligibility criteria:
inclusion criteria: * adult males and females between 35 and 90 years of age * status post skin cancer removal on the scalp, ear or leg with a wound that would otherwise be allowed to heal by secondary intention or grafting * wound considered appropriate by physician to receive epidermal grafting * willingness to participate in study by evidence of informed consent exclusion criteria: * female patients reported to be breastfeeding, pregnant or planning to become pregnant * clinical signs of infection * subjects currently on immunosuppressive medications, chemotherapy or a cytotoxic agent * participation in another interventional study with potential exposure to an investigational drug or device within the past 30 days or planned study entry within 90 days after study entrance.

Keywords: mohs surgery excisional skin surgery micrografting